Links
Visit HCV Advocate for current clinical trial information indexed by pharmaceutical company; AbbVie, Bristol-Myers Squibb (BMS), Gilead, Merck, and Tibotec / Janssen, for drugs currently in Phase 2 and 3 clinical development check out HCV drug pipeline, with comments here, and FDA approved medications for HCV here.
May clinical trial updates
Monday, May 11, 2015, 12:00:00 PM
ClinicalTrials.gov Identifier:
NCT02442284
NCT02442284
Conditions: Chronic Hepatitis C; Cirrhosis; Hepatitis C Virus
Interventions: Drug: Ombitasvir; Drug: Paritaprevir; Drug: Ritonavir; Drug: Dasabuvir; Drug: Ribavirin
Sponsor: AbbVie
Not yet recruiting - verified May 2015
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
Monday, May 11, 2015, 12:00:00 PM
Interventions: Drug: Ombitasvir; Drug: Paritaprevir; Drug: Ritonavir; Drug: Dasabuvir; Drug: Ribavirin
Sponsor: AbbVie
Not yet recruiting - verified May 2015
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
Monday, May 11, 2015, 12:00:00 PM
ClinicalTrials.gov Identifier:
NCT02442271
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir; Drug: Dasabuvir; Drug: Ribavirin
Sponsor: AbbVie
Recruiting - verified May 2015
Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality
Wednesday, April 22, 2015, 12:00:00 PM
Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir; Drug: Dasabuvir; Drug: Ribavirin
Sponsor: AbbVie
Recruiting - verified May 2015
Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality
Wednesday, April 22, 2015, 12:00:00 PM
ClinicalTrials.gov Identifier:
NCT02427204
NCT02427204
Condition: Hepatitis C Infection
Intervention:
Sponsors: Mount Sinai School of Medicine; Gilead Sciences
Not yet recruiting - verified April 2015
A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
Wednesday, April 15, 2015, 12:00:00 PM
Intervention:
Sponsors: Mount Sinai School of Medicine; Gilead Sciences
Not yet recruiting - verified April 2015
A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
Wednesday, April 15, 2015, 12:00:00 PM
ClinicalTrials.gov Identifier:
NCT02421211
NCT02421211
Condition: Hepatitis C, Chronic
Interventions: Drug: Simeprevir (SMV); Drug: Ledipasvir (LDV); Drug: Sofosbuvir (SOF)
Sponsor: Janssen Sciences Ireland UC
Not yet recruiting - verified May 2015
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection
Tuesday, April 07, 2015, 12:00:00 PM
Interventions: Drug: Simeprevir (SMV); Drug: Ledipasvir (LDV); Drug: Sofosbuvir (SOF)
Sponsor: Janssen Sciences Ireland UC
Not yet recruiting - verified May 2015
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection
Tuesday, April 07, 2015, 12:00:00 PM
ClinicalTrials.gov Identifier:
NCT02413593
NCT02413593
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF; Drug: RBV
Sponsor: Gilead Sciences
Recruiting - verified May 2015
An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
Thursday, March 19, 2015, 12:00:00 PM
Interventions: Drug: LDV/SOF; Drug: RBV
Sponsor: Gilead Sciences
Recruiting - verified May 2015
An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
Thursday, March 19, 2015, 12:00:00 PM
ClinicalTrials.gov Identifier:
NCT02397395
NCT02397395
Conditions: Renal Impairment; End-stage Renal Disease
Interventions: Drug: Simeprevir (SMV) 150 mg; Drug: Daclatasvir (DCV) 60 mg
Sponsor: Janssen R&D Ireland
Not yet recruiting - verified April 2015
Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
Monday, March 16, 2015, 12:00:00 PM
Interventions: Drug: Simeprevir (SMV) 150 mg; Drug: Daclatasvir (DCV) 60 mg
Sponsor: Janssen R&D Ireland
Not yet recruiting - verified April 2015
Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
Monday, March 16, 2015, 12:00:00 PM
ClinicalTrials.gov Identifier:
NCT02392494
NCT02392494
Condition: Hepatitis C
Intervention: Drug: MK-1075
Sponsor: Merck Sharp & Dohme Corp.
Recruiting - verified May 2015
Intervention: Drug: MK-1075
Sponsor: Merck Sharp & Dohme Corp.
Recruiting - verified May 2015
No comments:
Post a Comment